iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction
iMODERN
Instantaneous Wave-free Ratio Guided Multi-vessel revascularizatiOn During Percutaneous Coronary intervEntion for Acute myocaRdial iNfarction (iMODERN)
1 other identifier
interventional
1,146
1 country
1
Brief Summary
In patients with acute ST-elevation myocardial infarction (STEMI), 40-60% have multi-vessel disease with an increased cardiovascular morbidity and mortality. Although it is not recommended to revascularize noninfarct lesions during the acute intervention, recent investigations suggest the opposite and show improved outcome after direct revascularization of noninfarct lesions. It is undesirable to risk procedure-related complications by treating noninfarct lesions without impaired flow. It is currently unknown whether pressure guided revascularization of noninfarct lesions in the acute phase improves outcome compared to the current guidelines. The iMODERN trial aims to compare an iFR-guided intervention of noninfarct lesions during the acute intervention with a deferred stress perfusion CMR-guided strategy during the outpatient follow-up, to determine the optimal therapeutic approach for STEMI patients with multivessel lesions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2017
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 18, 2017
CompletedFirst Posted
Study publicly available on registry
October 2, 2017
CompletedStudy Start
First participant enrolled
December 21, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 28, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2027
ExpectedAugust 14, 2026
August 1, 2026
7.9 years
September 18, 2017
August 12, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Composite end point of Major Adverse Cardiac Events
All-cause death, recurrent myocardial infarction and hospitalization for heart failure
3 years
Secondary Outcomes (13)
Composite end point of Major Adverse Cardiac Events
6 months, 12 months, and 5 years
Cardiac death
6 months, 12 months, 3 years, and 5 years
Myocardial infarction
6 months, 12 months, 3 years, and 5 years
Stroke
6 months, 12 months, 3 years, and 5 years
Transient ischemic attack
6 months, 12 months, 3 years, and 5 years
- +8 more secondary outcomes
Study Arms (2)
Active iFR-guided revascularization
EXPERIMENTALDecision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
Deferred CMR-guided revascularization
ACTIVE COMPARATORDecision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
Interventions
Eligibility Criteria
You may qualify if:
- Age 18 years and older
- Clinical presentation of STEMI and successful primary PCI within 12 hours from onset of symptoms
- One or more other, noninfarct coronary artery lesions of \>50% stenosis and feasible to be revascularized (i.e., minimal diameter 2mm)
You may not qualify if:
- History of ST-elevation myocardial infarction or coronary artery bypass graft
- Hemodynamic instability, respiratory failure, Kilips class ≥III
- Known GFR\<30 ml/min
- Known contra-indications for stress CMR (e.g.: severe claustrophobia, metal implants, severe renal failure, severe astma)
- Refusal or inability to provide informed consent
- Life expectancy due to noncardiovascular co-morbidity of less than 12 months
- Chronic total occlusion
- Left main stem stenosis (\>50%)
- Residual noninfarct lesion in infarct coronary artery
- Complex noninfarct target lesions
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Philips Medical Systemscollaborator
- Radboud University Medical Centerlead
- Biotronik AGcollaborator
- Stichting Life Sciences & Healthcollaborator
- Duke Cardiovascular Magnetic Resonance Centercollaborator
Study Sites (1)
Radboudumc
Nijmegen, Netherlands
Related Publications (3)
Nijveldt R, Maeng M, Beijnink CWH, Piek JJ, Al-Lamee RK, Raposo L, Baptista SB, Escaned J, Davies J, Klem I, Yosofi B, van Geuns RM, Frederiksen CA, Jakobsen L, El Barzouhi A, van der Heijden DJ, Ilhan M, Rasoul S, Brinckman S, Saraber C, Jones DA, Petersen SE, Podlesnikar T, Bunc M, Beijk MAM, Piers LH, van Rees JB, Seligman H, Cole G, Iglesias JF, Degrauwe S, van 't Hof AWJ, Lipsic E, Pundziute-do Prado G, Chattranukulchai P, Rodriguez-Palomares JF, Rigger J, Meuwissen M, Kleijn L, Pereira B, Monti L, van der Schaaf RJ, Sanchis J, Belli G, Tijssen JGP, Thim T, van Royen N; iMODERN Investigators. Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. N Engl J Med. 2026 Mar 5;394(10):958-968. doi: 10.1056/NEJMoa2512918. Epub 2025 Oct 28.
PMID: 41159879DERIVEDOng P, Martinez Pereyra V, Sechtem U, Bekeredjian R. Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022? Coron Artery Dis. 2022 Sep 1;33(6):485-489. doi: 10.1097/MCA.0000000000001157. Epub 2022 Jul 11.
PMID: 35811565DERIVEDBeijnink CWH, Thim T, van der Heijden DJ, Klem I, Al-Lamee R, Vos JL, Koop Y, Dijkgraaf MGW, Beijk MAM, Kim RJ, Davies J, Raposo L, Baptista SB, Escaned J, Piek JJ, Maeng M, van Royen N, Nijveldt R. Instantaneous wave-free ratio guided multivessel revascularisation during percutaneous coronary intervention for acute myocardial infarction: study protocol of the randomised controlled iMODERN trial. BMJ Open. 2021 Jan 15;11(1):e044035. doi: 10.1136/bmjopen-2020-044035.
PMID: 33452200DERIVED
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 18, 2017
First Posted
October 2, 2017
Study Start
December 21, 2017
Primary Completion
October 28, 2025
Study Completion (Estimated)
May 31, 2027
Last Updated
August 14, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share